KRAS and neoplasm: As in the metastatic setting, these data argue against employing Wnt inhibitors for APC-deficient tumours, but advocate their use for BRAF/KRAS-mutated serrated tumours that lack APC mutation (encompassing subsets of CMS1, CMS3, and CMS4 tumours) [63].